AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes

Journal of Gene Medicine

Volumn 10, Issue 2, 2008, Pages 132-142

  Andino, Lourdes M ^a   Takeda, Morihiko ^a   Kasahara, Hideko ^a   Jakymiw, Andrew ^a   Byrne, Barry J ^b   Lewin, Alfred S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Cardiomyocyte; Gene therapy; Heart; Phospholamban; RNA interference

Indexed keywords

CALCIUM ION; FURA 2; MESSENGER RNA; PARVOVIRUS VECTOR; PHOSPHOLAMBAN; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL CULTURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOSOL; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIME; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CELL LINE; CELL SEPARATION; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC VECTORS; HUMANS; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PLASMIDS; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

EID: 39449129592     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1131     Document Type: Article

References (37)

1. Piacentino V III, Weber CR, Chen X, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003; 92: 651 -658.
2. Chu G, Ferguson DG, Edes I, et al. Phospholamban ablation and compensatory responses in the mammalian heart. Ann N Y Acad Sci 1998; 853: 49-62.
3. Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994; 75: 401-409.
4. Minamisawa. S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999; 99: 313-322.
5. Sato Y, Kiriazis H, Yatani A, et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem 2001; 276: 9392-9399.
6. Iwanaga Y, Hoshijima M, Gu Y, et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 2004; 113: 727-736.
7. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002;8:864-871.
8. Dieterle T, Meyer M, Gu Y, et al. Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 2005; 67: 678-688.
9. Meyer M, Belke DD, Trost SU, et al. A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J 2004; 18: 1312-1314.
10. Del Monte F, Harding SE, Dec GW, et al. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002; 105: 904-907.
11. Fechner H, Suckau L, Kurreck J, et al. Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban. Gene Ther 2007; 14: 211-218.
12. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3:306-312.
13. Flotte TR. Recent developments in recombinant AAV-mediated gene therapy for lung diseases. Curr Gene Ther 2005; 5: 361-366.
14. Loiler SA, Conlon TJ, Song S, et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 2003; 10: 1551-1558.
15. Kaspar BK, Roth DM, Lai NC, et al. Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med 2005; 7: 316-324.
16. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Ther 2003; 10: 977-982.
17. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996; 3: 658-668.
18. Hernandez YJ, Wang J, Kearns WG, et al. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73: 8549-8S58.
19. Available: www.ambion.com.
20. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002; 28: 158-167.
21. Sadoshima J, Jahn L, Takahashi T, et al. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J Biol Chem 1992; 267: 10551-10560.
22. Porzio MA, Pearson AM. Improved resolution of myofibrillar proteins with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochim Biophys Acta 1977; 490: 27-34.
23. Combes A, Frye CS, Lemster BH, et al. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch 2002; 445: 246-256.
24. Kuznetsov V, Pak E, Robinson RB, et al. Beta 2-adrenergic receptor actions in neonatal and adult rat ventricular myocytes. Circ Res 1995; 76: 40-52.
25. Zhang JC, Woo YJ, Chen JA, et al. Efficient transmural cardiac gene transfer by intrapericardial injection in neonatal mice. J Mol Cell Cardiol 1999; 31: 721-732.
26. Ziolo MT, Martin JL, Bossuyt J, et al. Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function. Circ Res 2005; 96: 815-817.
27. Shankar P, Manjunath N, Lieberman J. The prospect of silencing disease using RNA interference. J Am Med Assn 2005; 293: 1367-1373.
28. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12: 1179-1187.
29. Marks AR. Calcium and the heart: a question of life and death. J Clin Invest 2003; 111: 597-600.
30. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
31. Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 111: 869-876.
32. Gao GP, Lu Y, Sun X, et al. High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes. J Virol 2006; 80: 6192-6194.
33. Wang Z, Ma HI, Li J, et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10: 2105-2111.
34. Du L, Kido M, Lee DV, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004; 10: 604-608.
35. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99: e3-e9.
36. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.
37. Palomeque J, Chemaly ER, Colosi P, et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 2007; 14: 989-997.